Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Announces COO Departure and Consulting Agreement
Summary
On October 10, 2024, Crinetics Pharmaceuticals, Inc. announced that James Hassard, its Chief Operating Officer, ceased serving effective October 14, 2024. The Company entered into a Consulting Agreement with Mr. Hassard, effective October 15, 2024 through January 15, 2025, under which he will provide up to 20 hours per month of services related to commercial activities and launch preparations. Additionally, the Company entered into a Separation and Release Agreement with Mr. Hassard, providing him with payments and benefits associated with a termination without cause. Mr. Hassard's outstanding equity awards will continue to vest through January 15, 2025.
Profitelligence Alerts
Get alerts for CRNX
Be first to know when Crinetics Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.
Official SEC Documents
Advertisement